Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection

Current Opinion in Investigational Drugs

Volumn 10, Issue 2, 2009, Pages 190-200

  Klibanov, O M ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALUMINUM MAGNESIUM HYDROXIDE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; OMEPRAZOLE; PLACEBO; RALTEGRAVIR; RIFABUTIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; ZIDOVUDINE;

AEROBIC METABOLISM; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE; VOMITING;

BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; QUINOLONES; RITONAVIR;

EID: 62249163679     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. 362362 Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schlief W, Blau C, Miller MD SCIENCE 2000 287 5453 646-650
2. 570705 Japan Tobacco Inc clinical development (as of October 20, 2004). Japan Tobacco Inc COMPANY WORLD WIDE WEB SITE 2004 October 20
3. 590953 Gilead and Japan Tobacco sign licensing agreement for novel HIV integrase inhibitor. Gilead Sciences Inc PRESS RELEASE 2005 March 22
4. 591479 JT concludes licensing agreement on JT's anti-HIV drug with Gilead. Japan Tobacco Inc PRESS RELEASE 2005 March 22
5. 593293 Gilead Sciences announces early termination of Hart-Scott-Rodino waiting period for the Japan Tobacco license for JTK-303. Gilead Sciences Inc PRESS RELEASE 2005 April 04
6. 664618 Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S et al J MED CHEM 2006 49 5 1506-1508 • Structural optimization of 4-quinolone-3-carboxylic acid through the addition of 2-fluoro and 3-chloro groups to the distal benzene ring at the C5-position of the quinoline ring improved the inhibition of strand transfer and antiviral activity. The addition of a hydroxyethyl group at the 1-position of the quinolone ring further improved the inhibition of strand transfer and antiviral activity. Finally, addition of a methoxy group at the 7-position of the quinolone ring and an isopropyl group at the 1S-position of the hydroxyethyl moiety provided elvitegravir with improved inhibition of strand transfer and antiviral activity. This paper also provides a synthesis route.
7. 10 copies/ml, respectively). Pharmacokinetics were doseproportional, and increased exposure was observed when elvitegravir was coadministered with ritonavir. Elvitegravir was generally well tolerated, and exhibited a similar safety profile to placebo.
8. 777607 Development of integrase inhibitors for treatment of AIDS: An overview. Dubey S, Satyanarayana YD, Lavania H EUR J MED CHEM 2007 42 9 1159-1168
9. 800621 Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. Daelemans D, Lu R, De Clercq E, Engelman A J VIROL 2007 81 8 4381-4385
10. 824806 Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Ramanathan S, Shen G, Cheng A, Kearney BP JAIDS-J ACQUIR IMMUNE DEFIC SYNDR 2007 45 3 274-279
11. 829908 Effect of atazanavir/r on the steady-state pharmacokinetics of elvitegravir. Mathias A, Ramanathan S, Hinkle J, West S, Enejosa D, Kearney D ICAAC 2007 47 September 19 Abs A-1417
12. 829910 A pharmacokinetic interaction between lopinavir/r and elvitegravir. Mathias A, West S, Enejosa J, Kearney B ICAAC 2007 47 September 19 Abs A-1418
13. 843333 Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney BP JAIDS-J ACQUIR IMMUNE DEFIC SYNDR 2007 46 2 160-166
14. 843779 Drug datasheet: Isentress. DRUG DATASHEET WEBSITE 2007 October 25
15. 915506 Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M ANTIMICROB AGENTS CHEMOTHER 2008 52 6 2069-2078
16. 926148 Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors. Goethals O, Clayton R, Wagemans E, Van Ginderen M, Vos A, Geluykens P, Dockx K, Smits V, Meersseman G, Jochmans D, Hallenberger S et al ANTIVIR THER 2008 13 Suppl 3 Abs 9
17. 927181 Gilead initiates phase III clinical trial of elvitegravir, an investigational integrase inhibitor for HIV. Gilead Sciences Inc PRESS RELEASE 2008 July 22
18. 937281 Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. Xu L, Anderson J, Ferns B, Cook P, Wildfire A, Workman J, Graham S, Smit E AIDS RES HUM RETROVIRUSES 2008 24 7 1003-1007
19. 939220 Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M et al J VIROL 2008 82 2 764-774
20. 10 copies/ ml). Data from this trial were also presented at the International Conference on Retroviruses and Opportunistic Infections [958850].
21. 939224 In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1. Ren C, May S, Miletti T, Bedard J ANTIVIR THER 2007 12 Suppl 3 Abs 1
22. 953643 Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. Mathias AA, Hinkle J, Shen G, Enejosa J, Piliero PJ, Sekar V, Mack R, Tomaka F, Kearney BP JAIDS-J ACQUIR IMMUNE DEFIC SYNDR 2008 49 2 156-162
23. 958150 Repair of gaps in retroviral DNA integration intermediates. Yoder KE, Bushman FD J VIROL 2000 74 23 11191-11200
24. 958158 JTK-303/GS 9137, a novel small-molecule inhibitor of HIV-1 integrase: Anti-HIV activity profile and pharmacokinetics in animals. Matsuzaki Y, Watanabe W, Yamataka K, Sato M, Enya S, Kano M, Kodama E, Matsuoka M, Ikeda S INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2006 13 Abs 508
25. 958163 Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2007 14 Abs 627
26. 958164 Human immunodeficiency virus type 2. Reeves JD, Doms RW J GEN VIROL 2002 83 6 1253-1265
27. 958843 Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, Gonzalez-Lahoz J J CLIN MICROBIOL 2000 38 4 1370-1374
28. 958844 HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, Campa P, Chene G, Brun-Vezinet F, Descamps D J ANTIMICROB CHEMOTHER 2008 62 5 914-920
29. 958846 Safety and pharmacokinetics of single oral dose of JTK-303/ GS 9137, a novel HIV integrase inhibitor, in healthy volunteers. Kawaguchi I, Ishikawa T, Ishibashi M, Irie S, Kakee A INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2006 13 Abs 580
30. 958847 Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125. Ramanathan S, West S, Kakuda TN, Mack R, Holmes C, Kearney BP ICAAC 2007 47 September 17-20 Abs H-1049
31. 958849 Pharmacokinetics of coadministered ritonavir-boosted elvitegravir plus maraviroc. Ramanathan S, West S, Abel S, Enejosa J, Kearney BP ICAAC 2007 47 September 17-20 Abs H-1050
32. 10 copies/ml; p = 0.02). Data from this trial were also presented at the HIV Drug Resistance Workshop [939223].
33. τ values were increased by 19.9-, 11.1- and 90-fold, respectively, and relative oral bioavailability was increased by 6- to 7-fold.
34. 959013 Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir. Ramanthan S, West S, Hui J, Chuck SL, Kearney BP INT WORKSHOP CLIN PHARMACOL HIV THER 2008 9 Abs O18
35. 959015 Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r. Ramanathan S, Mathias AA, Shen G, Holmes C, Kearney BP INT AIDS SOC CONF HIV PATHOGENESIS TREAT 2007 4 Abs WEPEB014
36. 959016 Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin. German PI, West S, Hui J, Kearney BP INT WORKSHOP CLIN PHARMACOL HIV THER 2008 9 Abs P19
37. 959017 Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney B INT WORKSHOP CLIN PHARMACOL HIV THER 2007 8 Abs 69
38. 959018 The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naive and experienced patients. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Cheng A, Kearney B INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2006 13 Abs 160LB
39. 969323 HIV/AIDS surveillance report: Cases of HIV infection and AIDS in the United States and dependent areas, 2005. Centers for Disease Controls and Prevention COMPANY PUBLICATION 2007 Volume 17, Revised Edition June 28
40. 970072 Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W ANTIVIR THER 2004 9 1 57-65
41. 971608 Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G et al J VIROL 2008 82 21 10366-10374
42. 971609 Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y BIOCHEMISTRY 2008 47 36 9345-9354
43. 971611 Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ AIDS 2008 22 14 1877-1880
44. 971795 Highlights of prescribing information: Isentress (raltegravir) tablets. Merck & Co Inc DRUG PACKAGE INSERT 2008 November 30
45. 972094 Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E J INFECT DIS 2004 189 1 51-60
46. 972095 GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W AIDS 2004 18 4 651-655